About us

Moexa Pharmaceuticals Limited (Moexa) is a multi national drug research and development company engaging in proprietary TGF-β/Smad3 signaling technology. We have pioneered this innovative treatment to address unmet medical needs in cancer immunotherapy, and in fibrotic disease.

The TGF-β/Smad3 pathway, is associated with tumor progression and fibrotic disease including lung fibrosis and cystic fibrosis. We have developed and continue to create and refine novel therapeutics focusing on the TGF-β/Smad3 signaling pathway.

Our proprietary small molecule Smad3 inhibitors demonstrate strong efficacy in pre-clinical animal model for cancers, and in preliminary tests for lung fibrosis. We have solid patents in place protecting our IP as we continue to expand our pipeline as we advance towards clinical trials.

TGF-β Smad3 Signaling Is A Key To Cancer & Fibrosis

TGF-β cytokines regulate cell fate decisions during development, tissue homeostasis and regeneration, and are major players in tumorigenesis, fibrotic disorders, immune malfunctions and various congenital diseases.

Effects of the TGF-β family are mediated by a combinatorial set of ligands and receptors and by a common set of receptor-activated mothers against decapentaplegic homologue (Smad) transcription factors.

Suppression of NK cell-mediated immuno surveillance via the Smad3-E4BP4 axis contributes to tumor development, cancer progression and fibrosis. Disruption of Smad3 is shown to reverse these effects.


Peer Review Summary:Smad3 Inhibition Prevents Cancer & Related Disease

Peer review of our original R&D acknowledges that Smad3 inhibitors can effectively block Smad3 phosphorylation, DNA binding and transcription. Tests on subjects with deactivated Smad3 confirm an upregulation of natural killer (NK) cells, which directly increase cancer killing activity. These tests also confirm a decrease in CD31, VEGF, which mediate angiogenesis and a decrease in MMPs, CXCR4, mediating matrix degradation. The combined effects our therapeutic process has been shown to positively reinforce the immune system while simultaneously leading to tumor suppression and prevention of metastasis.

Tumor development, and progression of cancer and most inflammatory diseases are contingent on diseased cell interaction in the tumor microenvironment. Transforming growth factor-b (TGF-β) is a known potent tumor promoter. Independent research confirms that, particularly in the case of cancer, Smad3-dependent microenvironment activation is essential in cancer growth, invasion, and metastasis (“cancer progression”). Tests on Smad3 deficient mice exhibit impaired mucosal immunity and diminished T cell responsiveness to TGF-β. Smad3 is clearly a key mediator of TGF-β/Smad signaling and plays a central role in the Smad-mediated transcriptional regulation.

In incidence of cancer, TGF-β Smad3 promotes tumor growth and cancer by suppressing NK cell immunity and promoting Treg response, angiogenesis, and MMPs activities. Targeting the Smad3-dependent tumor microenvironment with an inhibitor that deactivates Smad3 is a novel and effective therapy for cancer, and may be directly applicable to other related diseases involving Smad3 regulation.

It has been specifically confirmed that cancer cells produce abundant TGF-β to suppress the anti-cancer immunity from the host by inducing Treg cells, resulting in cancer evasion from the host immune surveillance. TGF-β also acts as a potent tumor promoter by stimulating angiogenesis, enhancing epithelial-mesenchymal transition (EMT), and activating the MMP system for ECM degradation.



TGF-β/Smad signaling has been long associated with tumour development in relation to phosphorylation in the Smad2/3 complex. Moexa NCE inhibitors prevent phosphorylation and up regulation of tumours elements while boosting NK cells production to revitalise the human immune system.


Moexa has developed a strategic patent library covering Mechanism of Action for anti-cancer and anti-fibrotic use. Patent rights have been established in the USA, Europe, China, Hong Kong, India, Canada and Australia.


Moexa offers a product expansion opportunity for a pharmaceutical looking to expand its pipeline with proprietary products in immune-therapy and anti-fibrotic therapeutics, including new SAR-CoVID treatments under development.


Latest News